DelveInsight Business Research LLP

DelveInsight’s “Intermittent Claudication Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Intermittent Claudication, historical and forecasted epidemiology as well as the Intermittent Claudication market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Intermittent Claudication market report provides current treatment practices, emerging drugs, Intermittent Claudication market share of the individual therapies, and current and forecasted Intermittent Claudication market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Intermittent Claudication treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Intermittent Claudication market.

Some of the key facts of the  Intermittent Claudication Market Report:

• The Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017) stated that the global prevalence of PAD was 120 million, representing 25.6% of the global burden of Cardiovascular disease and 1.7% of the overall global burden of disease.

• According to the American College of Cardiology (2020), PAD affects 8.5 million individuals in the US and becomes prevalent with age (greater than 20% of cases are in patients over 80 years).

Key Benefits of the Intermittent Claudication Market Report:

• The report covers the descriptive overview of Intermittent Claudication, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

• Comprehensive insight has been provided into the Intermittent Claudication epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Intermittent Claudication is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of the Intermittent Claudication market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Intermittent Claudication market

 Intermittent Claudication Overview

Intermittent Claudication is pain affecting the calf, and less commonly the thigh and buttock, that is induced by exercise and relieved by rest. Symptom severity varies from mild to severe. Intermittent claudication occurs as a result of muscle ischemia during exercise caused by obstruction to arterial flow. Intermittent claudication (IC) is defined by leg muscle pain, cramping, and fatigue brought on by ambulation/exercise; relieved on rest; and caused by inadequate blood supply and is the primary symptom of peripheral arterial disease (PAD). PAD has a detrimental effect on the quality of life. PAD is a debilitating atherosclerotic disease of the lower limbs and is associated with an increased risk of cardiovascular morbidity and mortality. IC is an extremely important marker of atheroma. Up to 60% of patients with IC have significant underlying coronary and/or carotid disease and 40% of all patients suffering from IC die or suffer a stroke within 5 years of presentation. The therapeutic intervention of IC essentially aims at providing symptomatic relief and reducing systemic cardiovascular complications. 

Intermittent Claudication Epidemiological Insights:

• Prevalence estimates for IC in previous studies vary from 0.4–14.4%. Compared to most previous reports, we observed low prevalence estimates for men in all age groups under the age of 60. However, among women in the same age groups, we found a higher prevalence than in most other studies.

• Intermittent claudication is pain affecting the calf, and less commonly the thigh and buttock, that is induced by exercise and relieved by rest. Symptom severity varies from mild to severe. Intermittent claudication occurs as a result of muscle ischaemia during exercise caused by obstruction to arterial flow. It is a common problem, with a prevalence of 0.6-10%1 which increases significantly with age. Almost a fifth of the population over the age of 65 has intermittent claudication,2 and, as a result of demographic changes in many developed countries, its prevalence in the general population is likely to rise dramatically over the next 20 years.

 Intermittent Claudication Epidemiological Segmentation 

• Total Intermittent Claudication prevelant cases 

• Total Intermittent Claudication gender specific prevelant cases 

• Total Intermittent Claudication diagnosed cases 

• Total Intermittent Claudication treatable cases 

Intermittent Claudication Market Outlook 

The Intermittent Claudication market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Intermittent Claudication market trends by analyzing the impact of current Intermittent Claudication therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Intermittent Claudication market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Intermittent Claudication market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Intermittent Claudication market in 7MM is expected to witness a major change in the study period 2019-2032.

 Intermittent Claudication Key Companies

• Pluristem

• Venturis Therapeutics, Inc.

• And many others 

Intermittent Claudication Therapies

• PLX-PAD

• FGF-1

• And many others 

Table of Contents

1. Key Insights 

2. Report Introduction 

3. Executive Summary of  Intermittent Claudication    

4. Disease Background and Overview

5. Epidemiology and patient population

6. Intermittent Claudication Emerging Therapies

7.  Intermittent Claudication Market Outlook

8. Market Access and Reimbursement of Therapies

9. Appendix

10.  Intermittent Claudication Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13.  About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/